Nutrient chapter

Moringa oleifera

Moringa oleifera is a botanical food and supplement. Fresh or dried leaf, leaf powder, tea, hydroethanolic extract, seed extract, glucomoringin and purified moringin are compositionally distinct actors.

27 recorded mechanisms · 1 availability situations · 1 preserved sources. Draft and verified records are labeled separately.

Read recorded mechanisms Open recursive mind map

The mechanisms

What the sources say this nutrient does, one relationship at a time. Plain wording comes first; the technical statement follows.

During standardized cold-water extraction of dried Moringa leaves, endogenous myrosinase converted glucomoringin to moringin; isothiocyanate yield was rapid and essentially complete after 30 minutes.
Glucomoringin → Moringin / MIC-1 source_derived_draftungraded
Experimental context and source evidence
dose
Calibrated cold-water extraction
duration
30 minutes
evidence_access
Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
evidence_scope
literature_reviewed; model-specific source-derived curation
experimental_model
Dried Moringa leaves and aqueous tea preparations
limitations
A standardized tea protocol does not establish the moringin dose in every household tea, cooked leaf, powder or capsule.
nutrient_topic
Moringa oleifera chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Moringa oleifera
organism
Dried Moringa leaves and aqueous tea preparations
plain_language
During standardized cold-water extraction of dried Moringa leaves, endogenous myrosinase converted glucomoringin to moringin; isothiocyanate yield was rapid and essentially complete after 30 minutes.
primary_references
A Strategy to Deliver Precise Oral Doses of the Glucosinolates or Isothiocyanates from Moringa oleifera Leaves for Use in Clinical Studies. (2019). https://pubmed.ncbi.nlm.nih.gov/31323988/ DOI: 10.3390/nu11071547
route
Ex vivo food preparation
tissue
Glucosinolate/isothiocyanate preparation chemistry
Moringa oleifera: mechanism of action and interactions (2026-09-20) · lines 13–22
Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Dried Moringa leaves and aqueous tea preparations · source_derived_draft · unverified_draft
## moringa-cold-water-myrosinase-conversion During standardized cold-water extraction of dried Moringa leaves, endogenous myrosinase converted glucomoringin to moringin; isothiocyanate yield was rapid and essentially complete after 30 minutes. Model/species: Dried Moringa leaves and aqueous tea preparations Tissue/system: Glucosinolate/isothiocyanate preparation chemistry Exposure: Calibrated cold-water extraction Route: Ex vivo food preparation Duration: 30 minutes Limits: A standardized tea protocol does not establish the moringin dose in every household tea, cooked leaf, powder or capsule. Primary reference: A Strategy to Deliver Precise Oral Doses of the Glucosinolates or Isothiocyanates from Moringa oleifera Leaves for Use in Clinical Studies. (2019). https://pubmed.ncbi.nlm.nih.gov/31323988/ DOI: 10.3390/nu11071547 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
Complete structured claim and evidence
Across 36 accessions grown in one garden, wild and domesticated Moringa differed in the relative abundance of glucomoringin and glucosoonjnain and in taste.
Moringa oleifera → Moringa leaf glucomoringin/glucosoonjnain profile source_derived_draftungraded
Experimental context and source evidence
dose
Common-garden cultivation
duration
Single harvest study
evidence_access
Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
evidence_scope
literature_reviewed; model-specific source-derived curation
experimental_model
Thirty-six wild and domesticated Moringa accessions
limitations
The result establishes accession-level variation and does not quantify a commercial product.
nutrient_topic
Moringa oleifera chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Moringa oleifera
organism
Thirty-six wild and domesticated Moringa accessions
plain_language
Across 36 accessions grown in one garden, wild and domesticated Moringa differed in the relative abundance of glucomoringin and glucosoonjnain and in taste.
primary_references
Wild and domesticated Moringa oleifera differ in taste, glucosinolate composition, and antioxidant potential, but not myrosinase activity or protein content. (2018). https://pubmed.ncbi.nlm.nih.gov/29789671/ DOI: 10.1038/s41598-018-26059-3
route
Plant sampling
tissue
Leaf composition and taste
Moringa oleifera: mechanism of action and interactions (2026-09-20) · lines 24–33
Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Thirty-six wild and domesticated Moringa accessions · source_derived_draft · unverified_draft
## moringa-accession-glucosinolate-variation Across 36 accessions grown in one garden, wild and domesticated Moringa differed in the relative abundance of glucomoringin and glucosoonjnain and in taste. Model/species: Thirty-six wild and domesticated Moringa accessions Tissue/system: Leaf composition and taste Exposure: Common-garden cultivation Route: Plant sampling Duration: Single harvest study Limits: The result establishes accession-level variation and does not quantify a commercial product. Primary reference: Wild and domesticated Moringa oleifera differ in taste, glucosinolate composition, and antioxidant potential, but not myrosinase activity or protein content. (2018). https://pubmed.ncbi.nlm.nih.gov/29789671/ DOI: 10.1038/s41598-018-26059-3 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
Complete structured claim and evidence
Wild and domesticated Moringa accessions did not differ significantly in measured leaf myrosinase activity, despite differing glucosinolate composition.
Moringa oleifera → Moringa oleifera myrosinase source_derived_draftungraded
Experimental context and source evidence
dose
Common-garden cultivation
duration
Single harvest study
evidence_access
Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
evidence_scope
literature_reviewed; model-specific source-derived curation
experimental_model
Thirty-six wild and domesticated Moringa accessions
limitations
A population-level null difference does not mean processing leaves myrosinase intact in every food preparation.
nutrient_topic
Moringa oleifera chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Moringa oleifera
organism
Thirty-six wild and domesticated Moringa accessions
plain_language
Wild and domesticated Moringa accessions did not differ significantly in measured leaf myrosinase activity, despite differing glucosinolate composition.
primary_references
Wild and domesticated Moringa oleifera differ in taste, glucosinolate composition, and antioxidant potential, but not myrosinase activity or protein content. (2018). https://pubmed.ncbi.nlm.nih.gov/29789671/ DOI: 10.1038/s41598-018-26059-3
route
Plant sampling
tissue
Leaf myrosinase activity
Moringa oleifera: mechanism of action and interactions (2026-09-20) · lines 35–44
Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Thirty-six wild and domesticated Moringa accessions · source_derived_draft · unverified_draft
## moringa-accession-myrosinase-null Wild and domesticated Moringa accessions did not differ significantly in measured leaf myrosinase activity, despite differing glucosinolate composition. Model/species: Thirty-six wild and domesticated Moringa accessions Tissue/system: Leaf myrosinase activity Exposure: Common-garden cultivation Route: Plant sampling Duration: Single harvest study Limits: A population-level null difference does not mean processing leaves myrosinase intact in every food preparation. Primary reference: Wild and domesticated Moringa oleifera differ in taste, glucosinolate composition, and antioxidant potential, but not myrosinase activity or protein content. (2018). https://pubmed.ncbi.nlm.nih.gov/29789671/ DOI: 10.1038/s41598-018-26059-3 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
Complete structured claim and evidence
Purified moringin acted as a potent agonist of human TRPA1 in vitro.
Moringin / MIC-1 → Human TRPA1 ion channel source_derived_draftungraded
Experimental context and source evidence
dose
Purified moringin concentration series
duration
Acute
evidence_access
Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
evidence_scope
literature_reviewed; model-specific source-derived curation
experimental_model
Human TRPA1-expressing in-vitro channel assay
limitations
Channel activation in an expression assay does not establish analgesia, pain, dose or tissue exposure in humans.
nutrient_topic
Moringa oleifera chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Moringa oleifera
organism
Human TRPA1-expressing in-vitro channel assay
plain_language
Purified moringin acted as a potent agonist of human TRPA1 in vitro.
primary_references
Moringin, A Stable Isothiocyanate from Moringa oleifera, Activates the Somatosensory and Pain Receptor TRPA1 Channel In Vitro. (2020). https://pubmed.ncbi.nlm.nih.gov/32098328/ DOI: 10.3390/molecules25040976
route
In vitro
tissue
Somatosensory ion-channel activation
Moringa oleifera: mechanism of action and interactions (2026-09-20) · lines 46–55
Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Human TRPA1-expressing in-vitro channel assay · source_derived_draft · unverified_draft
## moringa-moringin-trpa1 Purified moringin acted as a potent agonist of human TRPA1 in vitro. Model/species: Human TRPA1-expressing in-vitro channel assay Tissue/system: Somatosensory ion-channel activation Exposure: Purified moringin concentration series Route: In vitro Duration: Acute Limits: Channel activation in an expression assay does not establish analgesia, pain, dose or tissue exposure in humans. Primary reference: Moringin, A Stable Isothiocyanate from Moringa oleifera, Activates the Somatosensory and Pain Receptor TRPA1 Channel In Vitro. (2020). https://pubmed.ncbi.nlm.nih.gov/32098328/ DOI: 10.3390/molecules25040976 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
Complete structured claim and evidence
In the same in-vitro comparison, moringin did not activate or only weakly activated TRPV1, TRPV2, TRPV3, TRPV4 and TRPM8 relative to its TRPA1 activity.
Moringin / MIC-1 → Human TRPV1-TRPV4 and TRPM8 channel panel source_derived_draftungraded
Experimental context and source evidence
dose
Purified moringin
duration
Acute
evidence_access
Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
evidence_scope
literature_reviewed; model-specific source-derived curation
experimental_model
Human TRP-channel in-vitro assays
limitations
This selectivity result is assay-specific and does not exclude indirect effects on sensory signaling in vivo.
nutrient_topic
Moringa oleifera chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Moringa oleifera
organism
Human TRP-channel in-vitro assays
plain_language
In the same in-vitro comparison, moringin did not activate or only weakly activated TRPV1, TRPV2, TRPV3, TRPV4 and TRPM8 relative to its TRPA1 activity.
primary_references
Moringin, A Stable Isothiocyanate from Moringa oleifera, Activates the Somatosensory and Pain Receptor TRPA1 Channel In Vitro. (2020). https://pubmed.ncbi.nlm.nih.gov/32098328/ DOI: 10.3390/molecules25040976
route
In vitro
tissue
Channel selectivity panel
Moringa oleifera: mechanism of action and interactions (2026-09-20) · lines 57–66
Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Human TRP-channel in-vitro assays · source_derived_draft · unverified_draft
## moringa-moringin-trp-selectivity In the same in-vitro comparison, moringin did not activate or only weakly activated TRPV1, TRPV2, TRPV3, TRPV4 and TRPM8 relative to its TRPA1 activity. Model/species: Human TRP-channel in-vitro assays Tissue/system: Channel selectivity panel Exposure: Purified moringin Route: In vitro Duration: Acute Limits: This selectivity result is assay-specific and does not exclude indirect effects on sensory signaling in vivo. Primary reference: Moringin, A Stable Isothiocyanate from Moringa oleifera, Activates the Somatosensory and Pain Receptor TRPA1 Channel In Vitro. (2020). https://pubmed.ncbi.nlm.nih.gov/32098328/ DOI: 10.3390/molecules25040976 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
Complete structured claim and evidence
The standardized multi-constituent ME-D leaf preparation increased NRF2-regulated NQO1 and HMOX1 expression and cellular glutathione in BEAS-2B cells, and increased NRF2-regulated genes after oral dosing in mice.
Standardized palatable Moringa leaf preparation ME-D → NRF2-linked NQO1, HMOX1 and glutathione response to ME-D source_derived_draftungraded
Experimental context and source evidence
dose
Chemically profiled ME-D hot-soup or freeze-dried preparation
duration
Acute cell exposure and study-specified mouse dosing
evidence_access
Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
evidence_scope
literature_reviewed; model-specific source-derived curation
experimental_model
Human BEAS-2B cells and orally dosed mice
limitations
The preparation contained moringin, glucomoringin and polyphenols, so the response cannot be assigned to one constituent or treated as a human clinical outcome.
nutrient_topic
Moringa oleifera chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Moringa oleifera
organism
Human BEAS-2B cells and orally dosed mice
plain_language
The standardized multi-constituent ME-D leaf preparation increased NRF2-regulated NQO1 and HMOX1 expression and cellular glutathione in BEAS-2B cells, and increased NRF2-regulated genes after oral dosing in mice.
primary_references
Development of Moringa oleifera as functional food targeting NRF2 signaling: antioxidant and anti-inflammatory activity in experimental model systems. (2023). https://pubmed.ncbi.nlm.nih.gov/37114361/ DOI: 10.1039/d3fo00572k
route
In vitro and oral mouse exposure
tissue
NRF2-linked gene and glutathione responses
Moringa oleifera: mechanism of action and interactions (2026-09-20) · lines 68–77
Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Human BEAS-2B cells and orally dosed mice · source_derived_draft · unverified_draft
## moringa-standardized-preparation-nrf2 The standardized multi-constituent ME-D leaf preparation increased NRF2-regulated NQO1 and HMOX1 expression and cellular glutathione in BEAS-2B cells, and increased NRF2-regulated genes after oral dosing in mice. Model/species: Human BEAS-2B cells and orally dosed mice Tissue/system: NRF2-linked gene and glutathione responses Exposure: Chemically profiled ME-D hot-soup or freeze-dried preparation Route: In vitro and oral mouse exposure Duration: Acute cell exposure and study-specified mouse dosing Limits: The preparation contained moringin, glucomoringin and polyphenols, so the response cannot be assigned to one constituent or treated as a human clinical outcome. Primary reference: Development of Moringa oleifera as functional food targeting NRF2 signaling: antioxidant and anti-inflammatory activity in experimental model systems. (2023). https://pubmed.ncbi.nlm.nih.gov/37114361/ DOI: 10.1039/d3fo00572k Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
Complete structured claim and evidence
Brusatol treatment significantly diminished the ME-D-induced increase in NQO1 expression in BEAS-2B cells, supporting NRF2 dependence for that measured response.
Brusatol → NRF2-linked NQO1, HMOX1 and glutathione response to ME-D source_derived_draftungraded
Experimental context and source evidence
availability_state
machinery_impairment Imported condition classification; unverified.
dose
ME-D with brusatol
duration
Acute
evidence_access
Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
evidence_scope
literature_reviewed; model-specific source-derived curation
experimental_model
Human BEAS-2B cells
limitations
Brusatol is a pharmacological perturbation with effects beyond a nutritional setting; the experiment supports pathway dependence for NQO1, not every effect of Moringa.
nutrient_topic
Moringa oleifera chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Moringa oleifera
organism
Human BEAS-2B cells
plain_language
Brusatol treatment significantly diminished the ME-D-induced increase in NQO1 expression in BEAS-2B cells, supporting NRF2 dependence for that measured response.
primary_references
Development of Moringa oleifera as functional food targeting NRF2 signaling: antioxidant and anti-inflammatory activity in experimental model systems. (2023). https://pubmed.ncbi.nlm.nih.gov/37114361/ DOI: 10.1039/d3fo00572k
route
In vitro perturbation
tissue
Pharmacological NRF2 perturbation
trigger_kind
machinery_impairment Imported condition classification; unverified.
Moringa oleifera: mechanism of action and interactions (2026-09-20) · lines 79–88
Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Human BEAS-2B cells · source_derived_draft · unverified_draft
## moringa-brusatol-blocks-nrf2-response Brusatol treatment significantly diminished the ME-D-induced increase in NQO1 expression in BEAS-2B cells, supporting NRF2 dependence for that measured response. Model/species: Human BEAS-2B cells Tissue/system: Pharmacological NRF2 perturbation Exposure: ME-D with brusatol Route: In vitro perturbation Duration: Acute Limits: Brusatol is a pharmacological perturbation with effects beyond a nutritional setting; the experiment supports pathway dependence for NQO1, not every effect of Moringa. Primary reference: Development of Moringa oleifera as functional food targeting NRF2 signaling: antioxidant and anti-inflammatory activity in experimental model systems. (2023). https://pubmed.ncbi.nlm.nih.gov/37114361/ DOI: 10.1039/d3fo00572k Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
Complete structured claim and evidence
Cannabidiol plus moringin, each at 5 micromolar, produced larger changes in inflammatory, oxidative and apoptosis markers in LPS-stimulated murine macrophages than either constituent alone at that concentration.
Cannabidiol → Moringin / MIC-1 source_derived_draftungraded
Experimental context and source evidence
dose
Cannabidiol 5 micromolar plus moringin 5 micromolar
duration
Acute
evidence_access
Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
evidence_scope
literature_reviewed; model-specific source-derived curation
experimental_model
LPS-stimulated murine macrophages
limitations
This cell combination result does not establish clinical synergy, safety or dosing and should not be extrapolated to cannabis or whole Moringa products.
nutrient_topic
Moringa oleifera chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Moringa oleifera
organism
LPS-stimulated murine macrophages
plain_language
Cannabidiol plus moringin, each at 5 micromolar, produced larger changes in inflammatory, oxidative and apoptosis markers in LPS-stimulated murine macrophages than either constituent alone at that concentration.
primary_references
Anti-inflammatory and antioxidant effects of a combination of cannabidiol and moringin in LPS-stimulated macrophages. (2016). https://pubmed.ncbi.nlm.nih.gov/27215129/ DOI: 10.1016/j.fitote.2016.05.008
route
In vitro
tissue
TNF-alpha, IL-10, iNOS, NRF2, nitrotyrosine, BCL2, BAX and cleaved-caspase-3 panel
Moringa oleifera: mechanism of action and interactions (2026-09-20) · lines 90–99
Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · LPS-stimulated murine macrophages · source_derived_draft · unverified_draft
## moringa-cannabidiol-combination Cannabidiol plus moringin, each at 5 micromolar, produced larger changes in inflammatory, oxidative and apoptosis markers in LPS-stimulated murine macrophages than either constituent alone at that concentration. Model/species: LPS-stimulated murine macrophages Tissue/system: TNF-alpha, IL-10, iNOS, NRF2, nitrotyrosine, BCL2, BAX and cleaved-caspase-3 panel Exposure: Cannabidiol 5 micromolar plus moringin 5 micromolar Route: In vitro Duration: Acute Limits: This cell combination result does not establish clinical synergy, safety or dosing and should not be extrapolated to cannabis or whole Moringa products. Primary reference: Anti-inflammatory and antioxidant effects of a combination of cannabidiol and moringin in LPS-stimulated macrophages. (2016). https://pubmed.ncbi.nlm.nih.gov/27215129/ DOI: 10.1016/j.fitote.2016.05.008 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
Complete structured claim and evidence
A TRPV1 antagonist impaired cannabidiol efficacy in the macrophage assay but did not alter moringin activity; CB1 and CB2 antagonists affected neither route.
Human transient receptor potential vanilloid 1 / TRPV1 → TRPV1-sensitive cannabidiol efficacy but TRPV1-insensitive moringin efficacy in macrophages source_derived_draftungraded
Experimental context and source evidence
dose
Cannabidiol or moringin with TRPV1, CB1 or CB2 antagonists
duration
Acute
evidence_access
Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
evidence_scope
literature_reviewed; model-specific source-derived curation
experimental_model
LPS-stimulated murine macrophages
limitations
The abstract does not establish direct binding of either compound to every tested receptor, and the result is not a clinical interaction.
nutrient_topic
Moringa oleifera chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Moringa oleifera
organism
LPS-stimulated murine macrophages
plain_language
A TRPV1 antagonist impaired cannabidiol efficacy in the macrophage assay but did not alter moringin activity; CB1 and CB2 antagonists affected neither route.
primary_references
Anti-inflammatory and antioxidant effects of a combination of cannabidiol and moringin in LPS-stimulated macrophages. (2016). https://pubmed.ncbi.nlm.nih.gov/27215129/ DOI: 10.1016/j.fitote.2016.05.008
route
In vitro perturbation
tissue
Receptor-antagonist separation of combination components
Moringa oleifera: mechanism of action and interactions (2026-09-20) · lines 101–110
Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · LPS-stimulated murine macrophages · source_derived_draft · unverified_draft
## moringa-cannabidiol-trpv1-separation A TRPV1 antagonist impaired cannabidiol efficacy in the macrophage assay but did not alter moringin activity; CB1 and CB2 antagonists affected neither route. Model/species: LPS-stimulated murine macrophages Tissue/system: Receptor-antagonist separation of combination components Exposure: Cannabidiol or moringin with TRPV1, CB1 or CB2 antagonists Route: In vitro perturbation Duration: Acute Limits: The abstract does not establish direct binding of either compound to every tested receptor, and the result is not a clinical interaction. Primary reference: Anti-inflammatory and antioxidant effects of a combination of cannabidiol and moringin in LPS-stimulated macrophages. (2016). https://pubmed.ncbi.nlm.nih.gov/27215129/ DOI: 10.1016/j.fitote.2016.05.008 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
Complete structured claim and evidence
In ten healthy adults, a single 4 g dose of Moringa leaf powder increased insulin AUC and the insulin-to-glucose AUC ratio by 74% compared with the no-Moringa baseline.
Moringa dry leaf powder → Plasma insulin response to glucose challenge source_derived_draftungraded
Experimental context and source evidence
dose
Single 0, 1, 2 and 4 g leaf-powder doses separated by two weeks
duration
Six hours
evidence_access
Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
evidence_scope
literature_reviewed; model-specific source-derived curation
experimental_model
Ten healthy adults in an escalating-dose crossover study
limitations
The small nonrandomized dose sequence in healthy volunteers does not establish chronic glycemic benefit or an effect in diabetes.
nutrient_topic
Moringa oleifera chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Moringa oleifera
organism
Ten healthy adults in an escalating-dose crossover study
plain_language
In ten healthy adults, a single 4 g dose of Moringa leaf powder increased insulin AUC and the insulin-to-glucose AUC ratio by 74% compared with the no-Moringa baseline.
primary_references
Moringa Oleifera Leaf Increases Insulin Secretion after Single Dose Administration: A Preliminary Study in Healthy Subjects. (2016). https://pubmed.ncbi.nlm.nih.gov/27276742/
route
Oral
tissue
Plasma insulin and insulin/glucose AUC
Moringa oleifera: mechanism of action and interactions (2026-09-20) · lines 112–121
Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Ten healthy adults in an escalating-dose crossover study · source_derived_draft · unverified_draft
## moringa-human-acute-insulin In ten healthy adults, a single 4 g dose of Moringa leaf powder increased insulin AUC and the insulin-to-glucose AUC ratio by 74% compared with the no-Moringa baseline. Model/species: Ten healthy adults in an escalating-dose crossover study Tissue/system: Plasma insulin and insulin/glucose AUC Exposure: Single 0, 1, 2 and 4 g leaf-powder doses separated by two weeks Route: Oral Duration: Six hours Limits: The small nonrandomized dose sequence in healthy volunteers does not establish chronic glycemic benefit or an effect in diabetes. Primary reference: Moringa Oleifera Leaf Increases Insulin Secretion after Single Dose Administration: A Preliminary Study in Healthy Subjects. (2016). https://pubmed.ncbi.nlm.nih.gov/27276742/ Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
Complete structured claim and evidence
The same escalating-dose study found no difference in six-hour plasma glucose exposure after 0, 1, 2 or 4 g Moringa leaf powder.
Moringa dry leaf powder → Six-hour plasma glucose exposure after Moringa leaf powder source_derived_draftungraded
Experimental context and source evidence
dose
Single 0, 1, 2 and 4 g leaf-powder doses
duration
Six hours
evidence_access
Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
evidence_scope
literature_reviewed; model-specific source-derived curation
experimental_model
Ten healthy adults
limitations
A null acute glucose response in healthy adults does not exclude effects during chronic use or in dysglycemia.
nutrient_topic
Moringa oleifera chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Moringa oleifera
organism
Ten healthy adults
plain_language
The same escalating-dose study found no difference in six-hour plasma glucose exposure after 0, 1, 2 or 4 g Moringa leaf powder.
primary_references
Moringa Oleifera Leaf Increases Insulin Secretion after Single Dose Administration: A Preliminary Study in Healthy Subjects. (2016). https://pubmed.ncbi.nlm.nih.gov/27276742/
route
Oral
tissue
Plasma glucose concentration and AUC
Moringa oleifera: mechanism of action and interactions (2026-09-20) · lines 123–132
Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Ten healthy adults · source_derived_draft · unverified_draft
## moringa-human-acute-glucose-null The same escalating-dose study found no difference in six-hour plasma glucose exposure after 0, 1, 2 or 4 g Moringa leaf powder. Model/species: Ten healthy adults Tissue/system: Plasma glucose concentration and AUC Exposure: Single 0, 1, 2 and 4 g leaf-powder doses Route: Oral Duration: Six hours Limits: A null acute glucose response in healthy adults does not exclude effects during chronic use or in dysglycemia. Primary reference: Moringa Oleifera Leaf Increases Insulin Secretion after Single Dose Administration: A Preliminary Study in Healthy Subjects. (2016). https://pubmed.ncbi.nlm.nih.gov/27276742/ Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
Complete structured claim and evidence
In a 12-week double-blind trial in adults with prediabetes, 2.4 g/day Moringa dry leaf powder produced favorable fasting-glucose and HbA1c change scores relative to placebo.
Moringa dry leaf powder → Fasting glucose and HbA1c trajectory in adults with prediabetes source_derived_draftungraded
Experimental context and source evidence
dose
2.4 g/day dry leaf powder or placebo
duration
12 weeks
evidence_access
Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
evidence_scope
literature_reviewed; model-specific source-derived curation
experimental_model
Sixty-five randomized adults with prediabetes
limitations
The modest trial reports relative change trajectories and does not identify the active constituent or establish diabetes treatment efficacy.
nutrient_topic
Moringa oleifera chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Moringa oleifera
organism
Sixty-five randomized adults with prediabetes
plain_language
In a 12-week double-blind trial in adults with prediabetes, 2.4 g/day Moringa dry leaf powder produced favorable fasting-glucose and HbA1c change scores relative to placebo.
primary_references
Moringa oleifera Leaf Supplementation as a Glycemic Control Strategy in Subjects with Prediabetes. (2021). https://pubmed.ncbi.nlm.nih.gov/35010932/ DOI: 10.3390/nu14010057
route
Oral
tissue
Fasting blood glucose and HbA1c
Moringa oleifera: mechanism of action and interactions (2026-09-20) · lines 134–143
Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Sixty-five randomized adults with prediabetes · source_derived_draft · unverified_draft
## moringa-prediabetes-glycemia In a 12-week double-blind trial in adults with prediabetes, 2.4 g/day Moringa dry leaf powder produced favorable fasting-glucose and HbA1c change scores relative to placebo. Model/species: Sixty-five randomized adults with prediabetes Tissue/system: Fasting blood glucose and HbA1c Exposure: 2.4 g/day dry leaf powder or placebo Route: Oral Duration: 12 weeks Limits: The modest trial reports relative change trajectories and does not identify the active constituent or establish diabetes treatment efficacy. Primary reference: Moringa oleifera Leaf Supplementation as a Glycemic Control Strategy in Subjects with Prediabetes. (2021). https://pubmed.ncbi.nlm.nih.gov/35010932/ DOI: 10.3390/nu14010057 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
Complete structured claim and evidence
The same 12-week trial found no between-group differences in gut microbiota composition, hepatic or renal function markers, or the measured appetite-controlling hormones.
Moringa dry leaf powder → Gut microbiota, hepatic/renal markers and appetite-hormone panel in prediabetes source_derived_draftungraded
Experimental context and source evidence
dose
2.4 g/day dry leaf powder or placebo
duration
12 weeks
evidence_access
Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
evidence_scope
literature_reviewed; model-specific source-derived curation
experimental_model
Adults with prediabetes
limitations
The null applies to the measured endpoints, sample and exposure; it does not establish that every product is inert.
nutrient_topic
Moringa oleifera chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Moringa oleifera
organism
Adults with prediabetes
plain_language
The same 12-week trial found no between-group differences in gut microbiota composition, hepatic or renal function markers, or the measured appetite-controlling hormones.
primary_references
Moringa oleifera Leaf Supplementation as a Glycemic Control Strategy in Subjects with Prediabetes. (2021). https://pubmed.ncbi.nlm.nih.gov/35010932/ DOI: 10.3390/nu14010057
route
Oral
tissue
Microbiota, organ-function markers and appetite hormones
Moringa oleifera: mechanism of action and interactions (2026-09-20) · lines 145–154
Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Adults with prediabetes · source_derived_draft · unverified_draft
## moringa-prediabetes-metabolic-null The same 12-week trial found no between-group differences in gut microbiota composition, hepatic or renal function markers, or the measured appetite-controlling hormones. Model/species: Adults with prediabetes Tissue/system: Microbiota, organ-function markers and appetite hormones Exposure: 2.4 g/day dry leaf powder or placebo Route: Oral Duration: 12 weeks Limits: The null applies to the measured endpoints, sample and exposure; it does not establish that every product is inert. Primary reference: Moringa oleifera Leaf Supplementation as a Glycemic Control Strategy in Subjects with Prediabetes. (2021). https://pubmed.ncbi.nlm.nih.gov/35010932/ DOI: 10.3390/nu14010057 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
Complete structured claim and evidence
An ancillary analysis of the same 12-week prediabetes trial found no between-group differences in inflammatory markers, serum lipids, plasma antioxidant capacity or blood pressure.
Moringa dry leaf powder → Inflammatory, lipid, antioxidant-capacity and blood-pressure panel in prediabetes source_derived_draftungraded
Experimental context and source evidence
dose
2.4 g/day dry leaf powder or placebo
duration
12 weeks
evidence_access
Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
evidence_scope
literature_reviewed; model-specific source-derived curation
experimental_model
Adults with prediabetes from the same randomized trial
limitations
This shares participants and intervention with PMID 35010932 and is one dataset, not independent replication.
nutrient_topic
Moringa oleifera chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Moringa oleifera
organism
Adults with prediabetes from the same randomized trial
plain_language
An ancillary analysis of the same 12-week prediabetes trial found no between-group differences in inflammatory markers, serum lipids, plasma antioxidant capacity or blood pressure.
primary_references
Effects of Moringa oleifera Lam. Supplementation on Inflammatory and Cardiometabolic Markers in Subjects with Prediabetes. (2022). https://pubmed.ncbi.nlm.nih.gov/35565903/ DOI: 10.3390/nu14091937
route
Oral
tissue
Inflammatory and cardiometabolic biomarker panel
Moringa oleifera: mechanism of action and interactions (2026-09-20) · lines 156–165
Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Adults with prediabetes from the same randomized trial · source_derived_draft · unverified_draft
## moringa-prediabetes-cardiometabolic-null An ancillary analysis of the same 12-week prediabetes trial found no between-group differences in inflammatory markers, serum lipids, plasma antioxidant capacity or blood pressure. Model/species: Adults with prediabetes from the same randomized trial Tissue/system: Inflammatory and cardiometabolic biomarker panel Exposure: 2.4 g/day dry leaf powder or placebo Route: Oral Duration: 12 weeks Limits: This shares participants and intervention with PMID 35010932 and is one dataset, not independent replication. Primary reference: Effects of Moringa oleifera Lam. Supplementation on Inflammatory and Cardiometabolic Markers in Subjects with Prediabetes. (2022). https://pubmed.ncbi.nlm.nih.gov/35565903/ DOI: 10.3390/nu14091937 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
Complete structured claim and evidence
In a 40-person, 14-day randomized study of 20, 40 or 60 g/day Moringa leaves, adjusted end-of-intervention glucose, blood-pressure and lipid outcomes did not differ significantly among groups and changes were not dose-dependent.
Fresh Moringa leaves as eaten in the 14-day diabetes trial → Glucose, blood-pressure and lipid panel in adults with type 2 diabetes source_derived_draftungraded
Experimental context and source evidence
dose
0, 20, 40 or 60 g/day Moringa leaves with food
duration
14 days
evidence_access
Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
evidence_scope
literature_reviewed; model-specific source-derived curation
experimental_model
Forty adults with type 2 diabetes
limitations
The trial was small and short; within-group changes do not override the adjusted null between-group result.
nutrient_topic
Moringa oleifera chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Moringa oleifera
organism
Forty adults with type 2 diabetes
plain_language
In a 40-person, 14-day randomized study of 20, 40 or 60 g/day Moringa leaves, adjusted end-of-intervention glucose, blood-pressure and lipid outcomes did not differ significantly among groups and changes were not dose-dependent.
primary_references
Effects of Moringa oleifera leaves on the blood glucose, blood pressure, and lipid profile of type 2 diabetic subjects: A parallel group randomized clinical trial of efficacy. (2025). https://pubmed.ncbi.nlm.nih.gov/37229639/ DOI: 10.1177/02601060231176873
route
Oral food
tissue
Fasting glucose, blood pressure and lipid profile
Moringa oleifera: mechanism of action and interactions (2026-09-20) · lines 167–176
Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Forty adults with type 2 diabetes · source_derived_draft · unverified_draft
## moringa-type2-diabetes-dose-null In a 40-person, 14-day randomized study of 20, 40 or 60 g/day Moringa leaves, adjusted end-of-intervention glucose, blood-pressure and lipid outcomes did not differ significantly among groups and changes were not dose-dependent. Model/species: Forty adults with type 2 diabetes Tissue/system: Fasting glucose, blood pressure and lipid profile Exposure: 0, 20, 40 or 60 g/day Moringa leaves with food Route: Oral food Duration: 14 days Limits: The trial was small and short; within-group changes do not override the adjusted null between-group result. Primary reference: Effects of Moringa oleifera leaves on the blood glucose, blood pressure, and lipid profile of type 2 diabetic subjects: A parallel group randomized clinical trial of efficacy. (2025). https://pubmed.ncbi.nlm.nih.gov/37229639/ DOI: 10.1177/02601060231176873 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
Complete structured claim and evidence
In eleven evaluable adults with HIV, 1.85 g/day Moringa leaf powder for 14 days did not significantly alter steady-state nevirapine AUC, Cmax or 12-hour concentration.
Moringa dry leaf powder → Steady-state nevirapine AUC, Cmax and 12-hour concentration source_derived_draftungraded
Experimental context and source evidence
dose
Nevirapine alone then with 1.85 g/day Moringa leaf powder
duration
14 days coadministration
evidence_access
Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
evidence_scope
literature_reviewed; model-specific source-derived curation
experimental_model
Adults with HIV receiving steady-state nevirapine
limitations
The small one-sequence study supports a null at this product and dose, not absence of interaction with every drug or preparation.
nutrient_topic
Moringa oleifera chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Moringa oleifera
organism
Adults with HIV receiving steady-state nevirapine
plain_language
In eleven evaluable adults with HIV, 1.85 g/day Moringa leaf powder for 14 days did not significantly alter steady-state nevirapine AUC, Cmax or 12-hour concentration.
primary_references
Effect of Moringa oleifera Lam. leaf powder on the pharmacokinetics of nevirapine in HIV-infected adults: a one sequence cross-over study. (2017). https://pubmed.ncbi.nlm.nih.gov/28293270/ DOI: 10.1186/s12981-017-0140-4
route
Oral
tissue
Intensive 12-hour nevirapine pharmacokinetics
Moringa oleifera: mechanism of action and interactions (2026-09-20) · lines 178–187
Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Adults with HIV receiving steady-state nevirapine · source_derived_draft · unverified_draft
## moringa-nevirapine-pk-null In eleven evaluable adults with HIV, 1.85 g/day Moringa leaf powder for 14 days did not significantly alter steady-state nevirapine AUC, Cmax or 12-hour concentration. Model/species: Adults with HIV receiving steady-state nevirapine Tissue/system: Intensive 12-hour nevirapine pharmacokinetics Exposure: Nevirapine alone then with 1.85 g/day Moringa leaf powder Route: Oral Duration: 14 days coadministration Limits: The small one-sequence study supports a null at this product and dose, not absence of interaction with every drug or preparation. Primary reference: Effect of Moringa oleifera Lam. leaf powder on the pharmacokinetics of nevirapine in HIV-infected adults: a one sequence cross-over study. (2017). https://pubmed.ncbi.nlm.nih.gov/28293270/ DOI: 10.1186/s12981-017-0140-4 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
Complete structured claim and evidence
In twenty healthy volunteers, concurrent Moringa leaf powder lowered amodiaquine Cmax, while seven-day pretreatment increased desethylamodiaquine Cmax and AUC; desethylamodiaquine AUC rose 40.4% with concurrent dosing and 188% after pretreatment.
Moringa dry leaf powder → Human amodiaquine and desethylamodiaquine pharmacokinetic exposure source_derived_draftungraded
Experimental context and source evidence
dose
Single amodiaquine 10 mg/kg with concurrent 3 g Moringa or after 3 g/day for seven days
duration
Concurrent dose or seven-day pretreatment
evidence_access
Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
evidence_scope
literature_reviewed; model-specific source-derived curation
experimental_model
Twenty healthy adults in a three-period study
limitations
Pharmacokinetic changes may not translate directly to efficacy or toxicity; the open sequence and specific powder schedule limit generalization.
nutrient_topic
Moringa oleifera chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Moringa oleifera
organism
Twenty healthy adults in a three-period study
plain_language
In twenty healthy volunteers, concurrent Moringa leaf powder lowered amodiaquine Cmax, while seven-day pretreatment increased desethylamodiaquine Cmax and AUC; desethylamodiaquine AUC rose 40.4% with concurrent dosing and 188% after pretreatment.
primary_references
Moringa oleifera leaf powder alters the pharmacokinetics of amodiaquine in healthy human volunteers. (2018). https://pubmed.ncbi.nlm.nih.gov/29920710/ DOI: 10.1111/jcpt.12725
route
Oral
tissue
Amodiaquine and desethylamodiaquine plasma pharmacokinetics
Moringa oleifera: mechanism of action and interactions (2026-09-20) · lines 189–198
Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Twenty healthy adults in a three-period study · source_derived_draft · unverified_draft
## moringa-amodiaquine-pk-interaction In twenty healthy volunteers, concurrent Moringa leaf powder lowered amodiaquine Cmax, while seven-day pretreatment increased desethylamodiaquine Cmax and AUC; desethylamodiaquine AUC rose 40.4% with concurrent dosing and 188% after pretreatment. Model/species: Twenty healthy adults in a three-period study Tissue/system: Amodiaquine and desethylamodiaquine plasma pharmacokinetics Exposure: Single amodiaquine 10 mg/kg with concurrent 3 g Moringa or after 3 g/day for seven days Route: Oral Duration: Concurrent dose or seven-day pretreatment Limits: Pharmacokinetic changes may not translate directly to efficacy or toxicity; the open sequence and specific powder schedule limit generalization. Primary reference: Moringa oleifera leaf powder alters the pharmacokinetics of amodiaquine in healthy human volunteers. (2018). https://pubmed.ncbi.nlm.nih.gov/29920710/ DOI: 10.1111/jcpt.12725 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
Complete structured claim and evidence
Moringa methanolic and aqueous leaf extracts inhibited CYP3A4-mediated testosterone 6-beta-hydroxylation in mixed-sex human liver microsomes, with reported IC50 values of 0.5 and 2.5 mg/mL.
Aqueous and methanolic Moringa leaf extracts → Human CYP3A4 activity, probe and compartment specified source_derived_draftungraded
Experimental context and source evidence
dose
Leaf extracts from 0.01 to 10 mg/mL
duration
Incubation interval specified in the primary article
evidence_access
Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
evidence_scope
literature_reviewed; model-specific source-derived curation
experimental_model
Mixed-sex human liver microsomes
limitations
Extract concentrations and microsomal inhibition do not predict a clinical interaction without constituent exposure and intestinal/hepatic concentrations.
nutrient_topic
Moringa oleifera chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Moringa oleifera
organism
Mixed-sex human liver microsomes
plain_language
Moringa methanolic and aqueous leaf extracts inhibited CYP3A4-mediated testosterone 6-beta-hydroxylation in mixed-sex human liver microsomes, with reported IC50 values of 0.5 and 2.5 mg/mL.
primary_references
Moringa oleifera leaf extracts inhibit 6beta-hydroxylation of testosterone by CYP3A4. (2008). https://pubmed.ncbi.nlm.nih.gov/19745507/ DOI: 10.3855/jidc.201
route
In vitro
tissue
CYP3A4 testosterone 6-beta-hydroxylation
Moringa oleifera: mechanism of action and interactions (2026-09-20) · lines 200–209
Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Mixed-sex human liver microsomes · source_derived_draft · unverified_draft
## moringa-leaf-extract-cyp3a4 Moringa methanolic and aqueous leaf extracts inhibited CYP3A4-mediated testosterone 6-beta-hydroxylation in mixed-sex human liver microsomes, with reported IC50 values of 0.5 and 2.5 mg/mL. Model/species: Mixed-sex human liver microsomes Tissue/system: CYP3A4 testosterone 6-beta-hydroxylation Exposure: Leaf extracts from 0.01 to 10 mg/mL Route: In vitro Duration: Incubation interval specified in the primary article Limits: Extract concentrations and microsomal inhibition do not predict a clinical interaction without constituent exposure and intestinal/hepatic concentrations. Primary reference: Moringa oleifera leaf extracts inhibit 6beta-hydroxylation of testosterone by CYP3A4. (2008). https://pubmed.ncbi.nlm.nih.gov/19745507/ DOI: 10.3855/jidc.201 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
Complete structured claim and evidence
Several isolated Moringa leaf metabolites inhibited CYP3A4 at 41.5-100 micromolar but showed no remarkable CYP2D6 inhibition in the same in-vitro panel.
Omoringone and other isolated Moringa leaf CYP3A4 inhibitors → Human cytochrome P450 3A4 source_derived_draftungraded
Experimental context and source evidence
dose
Isolated constituents up to the assay range
duration
Acute
evidence_access
Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
evidence_scope
literature_reviewed; model-specific source-derived curation
experimental_model
Recombinant or assay-system human CYP3A4/CYP2D6 panel
limitations
Bioavailability was unresolved, so these concentrations cannot be treated as expected human exposure or used to predict a specific medicine interaction.
nutrient_topic
Moringa oleifera chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Moringa oleifera
organism
Recombinant or assay-system human CYP3A4/CYP2D6 panel
plain_language
Several isolated Moringa leaf metabolites inhibited CYP3A4 at 41.5-100 micromolar but showed no remarkable CYP2D6 inhibition in the same in-vitro panel.
primary_references
Isolation, synthesis, and drug interaction potential of secondary metabolites derived from the leaves of miracle tree (Moringa oleifera) against CYP3A4 and CYP2D6 isozymes. (2019). https://pubmed.ncbi.nlm.nih.gov/31301970/ DOI: 10.1016/j.phymed.2019.153010
route
In vitro
tissue
CYP isozyme inhibition
Moringa oleifera: mechanism of action and interactions (2026-09-20) · lines 211–220
Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Recombinant or assay-system human CYP3A4/CYP2D6 panel · source_derived_draft · unverified_draft
## moringa-isolated-constituent-cyp-selectivity Several isolated Moringa leaf metabolites inhibited CYP3A4 at 41.5-100 micromolar but showed no remarkable CYP2D6 inhibition in the same in-vitro panel. Model/species: Recombinant or assay-system human CYP3A4/CYP2D6 panel Tissue/system: CYP isozyme inhibition Exposure: Isolated constituents up to the assay range Route: In vitro Duration: Acute Limits: Bioavailability was unresolved, so these concentrations cannot be treated as expected human exposure or used to predict a specific medicine interaction. Primary reference: Isolation, synthesis, and drug interaction potential of secondary metabolites derived from the leaves of miracle tree (Moringa oleifera) against CYP3A4 and CYP2D6 isozymes. (2019). https://pubmed.ncbi.nlm.nih.gov/31301970/ DOI: 10.1016/j.phymed.2019.153010 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
Complete structured claim and evidence
Adding 5% peanut oil to Moringa leaves during simulated digestion increased beta-carotene and lutein micellarization, particularly beta-carotene, before uptake by Caco-2 cells.
Peanut oil → Beta-carotene and lutein micellarization from Moringa leaves source_derived_draftungraded
Experimental context and source evidence
dose
Fresh or lyophilized leaves with 5% peanut oil
duration
Digestion and uptake time course
evidence_access
Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
evidence_scope
literature_reviewed; model-specific source-derived curation
experimental_model
Simulated digestion coupled to human Caco-2 cells
limitations
This food-matrix result supports a fat effect on bioaccessibility but does not quantify human vitamin A status.
nutrient_topic
Moringa oleifera chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Moringa oleifera
organism
Simulated digestion coupled to human Caco-2 cells
plain_language
Adding 5% peanut oil to Moringa leaves during simulated digestion increased beta-carotene and lutein micellarization, particularly beta-carotene, before uptake by Caco-2 cells.
primary_references
Micellarization and intestinal cell uptake of beta-carotene and lutein from drumstick (Moringa oleifera) leaves. (2007). https://pubmed.ncbi.nlm.nih.gov/17651060/ DOI: 10.1089/jmf.2006.250
route
In vitro digestion
tissue
Carotenoid micellarization and cell accumulation
Moringa oleifera: mechanism of action and interactions (2026-09-20) · lines 222–231
Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Simulated digestion coupled to human Caco-2 cells · source_derived_draft · unverified_draft
## moringa-peanut-oil-carotenoid-bioaccessibility Adding 5% peanut oil to Moringa leaves during simulated digestion increased beta-carotene and lutein micellarization, particularly beta-carotene, before uptake by Caco-2 cells. Model/species: Simulated digestion coupled to human Caco-2 cells Tissue/system: Carotenoid micellarization and cell accumulation Exposure: Fresh or lyophilized leaves with 5% peanut oil Route: In vitro digestion Duration: Digestion and uptake time course Limits: This food-matrix result supports a fat effect on bioaccessibility but does not quantify human vitamin A status. Primary reference: Micellarization and intestinal cell uptake of beta-carotene and lutein from drumstick (Moringa oleifera) leaves. (2007). https://pubmed.ncbi.nlm.nih.gov/17651060/ DOI: 10.1089/jmf.2006.250 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
Complete structured claim and evidence
In fifteen well-nourished young children, intrinsically labeled beta-carotene from pureed Moringa leaves had 28% relative bioefficacy and an estimated vitamin A equivalence of 3.3:1 by weight.
All-trans-beta-carotene → Vitamin A source_derived_draftungraded
Experimental context and source evidence
dose
Pureed labeled Moringa leaves providing 1 mg beta-carotene plus a reference retinyl-acetate dose
duration
Thirty-five-day isotope sampling
evidence_access
Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
evidence_scope
literature_reviewed; model-specific source-derived curation
experimental_model
Fifteen Mexican children aged 17-35 months
limitations
Children were well nourished with adequate vitamin A stores; the estimate may differ with deficiency, food matrix, genetics and infection.
nutrient_topic
Moringa oleifera chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Moringa oleifera
organism
Fifteen Mexican children aged 17-35 months
plain_language
In fifteen well-nourished young children, intrinsically labeled beta-carotene from pureed Moringa leaves had 28% relative bioefficacy and an estimated vitamin A equivalence of 3.3:1 by weight.
primary_references
Use of a "Super-child" Approach to Assess the Vitamin A Equivalence of Moringa oleifera Leaves, Develop a Compartmental Model for Vitamin A Kinetics, and Estimate Vitamin A Total Body Stores in Young Mexican Children. (2017). https://pubmed.ncbi.nlm.nih.gov/28931584/ DOI: 10.3945/jn.117.256974
route
Oral
tissue
Stable-isotope plasma retinol kinetics
Moringa oleifera: mechanism of action and interactions (2026-09-20) · lines 233–242
Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Fifteen Mexican children aged 17-35 months · source_derived_draft · unverified_draft
## moringa-child-vitamin-a-equivalence In fifteen well-nourished young children, intrinsically labeled beta-carotene from pureed Moringa leaves had 28% relative bioefficacy and an estimated vitamin A equivalence of 3.3:1 by weight. Model/species: Fifteen Mexican children aged 17-35 months Tissue/system: Stable-isotope plasma retinol kinetics Exposure: Pureed labeled Moringa leaves providing 1 mg beta-carotene plus a reference retinyl-acetate dose Route: Oral Duration: Thirty-five-day isotope sampling Limits: Children were well nourished with adequate vitamin A stores; the estimate may differ with deficiency, food matrix, genetics and infection. Primary reference: Use of a "Super-child" Approach to Assess the Vitamin A Equivalence of Moringa oleifera Leaves, Develop a Compartmental Model for Vitamin A Kinetics, and Estimate Vitamin A Total Body Stores in Young Mexican Children. (2017). https://pubmed.ncbi.nlm.nih.gov/28931584/ DOI: 10.3945/jn.117.256974 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
Complete structured claim and evidence
In a six-week pilot feeding study, Moringa-fortified complementary foods produced only marginal, nonsignificant blood-retinol increases, and all infants remained vitamin A deficient.
Complementary infant foods fortified with Moringa leaf powder → Blood retinol concentration in vitamin-A-deficient infants source_derived_draftungraded
Experimental context and source evidence
dose
Two Moringa-fortified foods versus a cereal-legume control
duration
Six weeks
evidence_access
Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
evidence_scope
literature_reviewed; model-specific source-derived curation
experimental_model
Sixty-five completing infant-mother pairs in Ghana
limitations
The pilot had substantial attrition and short follow-up; its null result does not contradict measured carotenoid conversion in well-nourished children.
nutrient_topic
Moringa oleifera chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Moringa oleifera
organism
Sixty-five completing infant-mother pairs in Ghana
plain_language
In a six-week pilot feeding study, Moringa-fortified complementary foods produced only marginal, nonsignificant blood-retinol increases, and all infants remained vitamin A deficient.
primary_references
Improving Blood Retinol Concentrations with Complementary Foods Fortified with Moringa oleifera Leaf Powder - A Pilot Study. (2018). https://pubmed.ncbi.nlm.nih.gov/29962920/
route
Oral feeding
tissue
Whole-blood retinol
Moringa oleifera: mechanism of action and interactions (2026-09-20) · lines 244–253
Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Sixty-five completing infant-mother pairs in Ghana · source_derived_draft · unverified_draft
## moringa-infant-retinol-null In a six-week pilot feeding study, Moringa-fortified complementary foods produced only marginal, nonsignificant blood-retinol increases, and all infants remained vitamin A deficient. Model/species: Sixty-five completing infant-mother pairs in Ghana Tissue/system: Whole-blood retinol Exposure: Two Moringa-fortified foods versus a cereal-legume control Route: Oral feeding Duration: Six weeks Limits: The pilot had substantial attrition and short follow-up; its null result does not contradict measured carotenoid conversion in well-nourished children. Primary reference: Improving Blood Retinol Concentrations with Complementary Foods Fortified with Moringa oleifera Leaf Powder - A Pilot Study. (2018). https://pubmed.ncbi.nlm.nih.gov/29962920/ Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
Complete structured claim and evidence
In a three-month cluster-randomized pilot, 20 g/day maternal Moringa leaf powder did not change human-milk vitamin A concentration or maternal and infant serum vitamin A status, although milk alpha-carotene rose modestly.
Moringa dry leaf powder → Human-milk retinol concentration source_derived_draftungraded
Experimental context and source evidence
dose
Corn porridge with or without 20 g/day leaf powder
duration
Three months
evidence_access
Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
evidence_scope
literature_reviewed; model-specific source-derived curation
experimental_model
Forty-four completing Kenyan breastfeeding mother-infant pairs
limitations
The small pilot had baseline alpha-carotene imbalance and was not powered to establish clinical infant benefit.
nutrient_topic
Moringa oleifera chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Moringa oleifera
organism
Forty-four completing Kenyan breastfeeding mother-infant pairs
plain_language
In a three-month cluster-randomized pilot, 20 g/day maternal Moringa leaf powder did not change human-milk vitamin A concentration or maternal and infant serum vitamin A status, although milk alpha-carotene rose modestly.
primary_references
Impact of Maternal Moringa oleifera Leaf Supplementation on Milk and Serum Vitamin A and Carotenoid Concentrations in a Cohort of Breastfeeding Kenyan Women and Their Infants. (2024). https://pubmed.ncbi.nlm.nih.gov/39408390/ DOI: 10.3390/nu16193425
route
Maternal oral feeding
tissue
Milk retinol/carotenoids and serum retinol-binding protein
Moringa oleifera: mechanism of action and interactions (2026-09-20) · lines 255–264
Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Forty-four completing Kenyan breastfeeding mother-infant pairs · source_derived_draft · unverified_draft
## moringa-maternal-milk-retinol-null In a three-month cluster-randomized pilot, 20 g/day maternal Moringa leaf powder did not change human-milk vitamin A concentration or maternal and infant serum vitamin A status, although milk alpha-carotene rose modestly. Model/species: Forty-four completing Kenyan breastfeeding mother-infant pairs Tissue/system: Milk retinol/carotenoids and serum retinol-binding protein Exposure: Corn porridge with or without 20 g/day leaf powder Route: Maternal oral feeding Duration: Three months Limits: The small pilot had baseline alpha-carotene imbalance and was not powered to establish clinical infant benefit. Primary reference: Impact of Maternal Moringa oleifera Leaf Supplementation on Milk and Serum Vitamin A and Carotenoid Concentrations in a Cohort of Breastfeeding Kenyan Women and Their Infants. (2024). https://pubmed.ncbi.nlm.nih.gov/39408390/ DOI: 10.3390/nu16193425 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
Complete structured claim and evidence
Aqueous Moringa leaf extract inhibited alpha-amylase and reduced sucrose digestion across six tested gastrointestinal segments in rat and in-vitro experiments.
Aqueous Moringa leaf extract → Pancreatic alpha-amylase catalytic activity source_derived_draftungraded
Experimental context and source evidence
dose
Study-specific aqueous leaf extract
duration
Acute assays
evidence_access
Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
evidence_scope
literature_reviewed; model-specific source-derived curation
experimental_model
Type-2-diabetic rats, gastrointestinal segments and enzyme assays
limitations
The extract composition and experimental concentrations do not establish the effect of ordinary leaf servings in humans.
nutrient_topic
Moringa oleifera chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Moringa oleifera
organism
Type-2-diabetic rats, gastrointestinal segments and enzyme assays
plain_language
Aqueous Moringa leaf extract inhibited alpha-amylase and reduced sucrose digestion across six tested gastrointestinal segments in rat and in-vitro experiments.
primary_references
Anti-hyperglycaemic activity of Moringa oleifera is partly mediated by carbohydrase inhibition and glucose-fibre binding. (2017). https://pubmed.ncbi.nlm.nih.gov/28336764/ DOI: 10.1042/BSR20170059
route
In vitro, ex vivo and in vivo
tissue
Carbohydrate breakdown
Moringa oleifera: mechanism of action and interactions (2026-09-20) · lines 266–275
Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Type-2-diabetic rats, gastrointestinal segments and enzyme assays · source_derived_draft · unverified_draft
## moringa-carbohydrase-sucrose Aqueous Moringa leaf extract inhibited alpha-amylase and reduced sucrose digestion across six tested gastrointestinal segments in rat and in-vitro experiments. Model/species: Type-2-diabetic rats, gastrointestinal segments and enzyme assays Tissue/system: Carbohydrate breakdown Exposure: Study-specific aqueous leaf extract Route: In vitro, ex vivo and in vivo Duration: Acute assays Limits: The extract composition and experimental concentrations do not establish the effect of ordinary leaf servings in humans. Primary reference: Anti-hyperglycaemic activity of Moringa oleifera is partly mediated by carbohydrase inhibition and glucose-fibre binding. (2017). https://pubmed.ncbi.nlm.nih.gov/28336764/ DOI: 10.1042/BSR20170059 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
Complete structured claim and evidence
The same aqueous leaf extract retarded intestinal glucose absorption in rat perfusion experiments and bound glucose in a fiber assay.
Aqueous Moringa leaf extract → Intestinal glucose absorption in the rat perfusion model source_derived_draftungraded
Experimental context and source evidence
dose
Study-specific aqueous leaf extract
duration
Acute
evidence_access
Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
evidence_scope
literature_reviewed; model-specific source-derived curation
experimental_model
Rat intestinal perfusion and glucose-fiber assay
limitations
Rat perfusion and fiber binding do not quantify post-meal glucose absorption in humans.
nutrient_topic
Moringa oleifera chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Moringa oleifera
organism
Rat intestinal perfusion and glucose-fiber assay
plain_language
The same aqueous leaf extract retarded intestinal glucose absorption in rat perfusion experiments and bound glucose in a fiber assay.
primary_references
Anti-hyperglycaemic activity of Moringa oleifera is partly mediated by carbohydrase inhibition and glucose-fibre binding. (2017). https://pubmed.ncbi.nlm.nih.gov/28336764/ DOI: 10.1042/BSR20170059
route
In situ and in vitro
tissue
Glucose absorption and binding
Moringa oleifera: mechanism of action and interactions (2026-09-20) · lines 277–286
Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Rat intestinal perfusion and glucose-fiber assay · source_derived_draft · unverified_draft
## moringa-intestinal-glucose-binding The same aqueous leaf extract retarded intestinal glucose absorption in rat perfusion experiments and bound glucose in a fiber assay. Model/species: Rat intestinal perfusion and glucose-fiber assay Tissue/system: Glucose absorption and binding Exposure: Study-specific aqueous leaf extract Route: In situ and in vitro Duration: Acute Limits: Rat perfusion and fiber binding do not quantify post-meal glucose absorption in humans. Primary reference: Anti-hyperglycaemic activity of Moringa oleifera is partly mediated by carbohydrase inhibition and glucose-fibre binding. (2017). https://pubmed.ncbi.nlm.nih.gov/28336764/ DOI: 10.1042/BSR20170059 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
Complete structured claim and evidence
In the type-2-diabetic rat experiment, Moringa extract did not significantly change pancreatic insulin concentration despite its effects on carbohydrate digestion and absorption.
Aqueous Moringa leaf extract → Pancreatic insulin concentration in type-2-diabetic rats source_derived_draftungraded
Experimental context and source evidence
dose
Study-specific aqueous leaf extract
duration
Study interval specified in the primary article
evidence_access
Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
evidence_scope
literature_reviewed; model-specific source-derived curation
experimental_model
Type-2-diabetic rats
limitations
This model-specific null does not negate the acute plasma-insulin finding in healthy humans; the actors, endpoint and exposure differ.
nutrient_topic
Moringa oleifera chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Moringa oleifera
organism
Type-2-diabetic rats
plain_language
In the type-2-diabetic rat experiment, Moringa extract did not significantly change pancreatic insulin concentration despite its effects on carbohydrate digestion and absorption.
primary_references
Anti-hyperglycaemic activity of Moringa oleifera is partly mediated by carbohydrase inhibition and glucose-fibre binding. (2017). https://pubmed.ncbi.nlm.nih.gov/28336764/ DOI: 10.1042/BSR20170059
route
In vivo
tissue
Pancreatic insulin concentration
Moringa oleifera: mechanism of action and interactions (2026-09-20) · lines 288–297
Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Type-2-diabetic rats · source_derived_draft · unverified_draft
## moringa-rat-insulin-null In the type-2-diabetic rat experiment, Moringa extract did not significantly change pancreatic insulin concentration despite its effects on carbohydrate digestion and absorption. Model/species: Type-2-diabetic rats Tissue/system: Pancreatic insulin concentration Exposure: Study-specific aqueous leaf extract Route: In vivo Duration: Study interval specified in the primary article Limits: This model-specific null does not negate the acute plasma-insulin finding in healthy humans; the actors, endpoint and exposure differ. Primary reference: Anti-hyperglycaemic activity of Moringa oleifera is partly mediated by carbohydrase inhibition and glucose-fibre binding. (2017). https://pubmed.ncbi.nlm.nih.gov/28336764/ DOI: 10.1042/BSR20170059 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
Complete structured claim and evidence
Oral hydroethanolic Moringa leaf extract caused biochemical and histological liver and kidney injury in female ICR mice after a single 2000 mg/kg dose and during 28-day dosing up to 1000 mg/kg/day.
Hydroethanolic Moringa leaf extract → Liver and kidney injury profile in female ICR mice source_derived_draftungraded
Experimental context and source evidence
dose
2000 mg/kg once or 125-1000 mg/kg/day hydroethanolic extract
duration
Acute or 28 days
evidence_access
Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
evidence_scope
literature_reviewed; model-specific source-derived curation
experimental_model
Female ICR mice
limitations
These concentrated high-dose mouse exposures do not define risk from culinary leaves, tea or labeled human supplement doses.
nutrient_topic
Moringa oleifera chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Moringa oleifera
organism
Female ICR mice
plain_language
Oral hydroethanolic Moringa leaf extract caused biochemical and histological liver and kidney injury in female ICR mice after a single 2000 mg/kg dose and during 28-day dosing up to 1000 mg/kg/day.
primary_references
Moringa oleifera hydorethanolic leaf extract induced acute and sub-acute hepato-nephrotoxicity in female ICR-mice. (2021). https://pubmed.ncbi.nlm.nih.gov/34886737/ DOI: 10.1177/00368504211004272
route
Oral gavage
tissue
Hematology, enzymes and liver/kidney histology
Moringa oleifera: mechanism of action and interactions (2026-09-20) · lines 299–308
Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Female ICR mice · source_derived_draft · unverified_draft
## moringa-high-dose-extract-toxicity Oral hydroethanolic Moringa leaf extract caused biochemical and histological liver and kidney injury in female ICR mice after a single 2000 mg/kg dose and during 28-day dosing up to 1000 mg/kg/day. Model/species: Female ICR mice Tissue/system: Hematology, enzymes and liver/kidney histology Exposure: 2000 mg/kg once or 125-1000 mg/kg/day hydroethanolic extract Route: Oral gavage Duration: Acute or 28 days Limits: These concentrated high-dose mouse exposures do not define risk from culinary leaves, tea or labeled human supplement doses. Primary reference: Moringa oleifera hydorethanolic leaf extract induced acute and sub-acute hepato-nephrotoxicity in female ICR-mice. (2021). https://pubmed.ncbi.nlm.nih.gov/34886737/ DOI: 10.1177/00368504211004272 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
Complete structured claim and evidence

Availability and dependencies

Each situation shows the normal role first, then what the sources report under a specific condition. A shortfall in the diet, a fault in the machinery, and a low blood reading are kept separate because they are not the same thing.

Blocking NRF2 suppresses one standardized Moringa response

Condition: machinery_impairment · Cells are treated with the NRF2 inhibitor brusatol.

Normal role: ME-D increases NRF2-linked NQO1 expression in the assay.

Recorded consequence: The ME-D-induced NQO1 increase is significantly diminished.

Scope: In-vitro pharmacological perturbation.

The sources

Every document behind this chapter is preserved word for word. Open one to read it in full with its recorded conflicts marked in place.

Moringa oleifera: mechanism of action and interactions (2026-09-20)Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · unverified_draftRead preserved source

Recorded disagreements

Where two sources say different things, both are kept and the difference is explained. You can discuss a disagreement or propose a mechanism that might account for it.

Open questions in this collection

Questions the curators could not answer from the sources in front of them, kept here with the reason each one is still open. These are gaps in this collection, not findings or proof that no one has studied them.

Chapters are assembled from supplied drafts and curated literature summaries. Statements remain unverified against the primary studies, and the ledger is not medical advice.

Evidence, AI assistance and curation standards

Moringa oleifera

The mechanisms

During standardized cold-water extraction of dried Moringa leaves, endogenous myrosinase converted glucomoringin to moringin; isothiocyanate yield was rapid and essentially complete after 30 minutes.

Across 36 accessions grown in one garden, wild and domesticated Moringa differed in the relative abundance of glucomoringin and glucosoonjnain and in taste.

Wild and domesticated Moringa accessions did not differ significantly in measured leaf myrosinase activity, despite differing glucosinolate composition.

Purified moringin acted as a potent agonist of human TRPA1 in vitro.

In the same in-vitro comparison, moringin did not activate or only weakly activated TRPV1, TRPV2, TRPV3, TRPV4 and TRPM8 relative to its TRPA1 activity.

The standardized multi-constituent ME-D leaf preparation increased NRF2-regulated NQO1 and HMOX1 expression and cellular glutathione in BEAS-2B cells, and increased NRF2-regulated genes after oral dosing in mice.

Brusatol treatment significantly diminished the ME-D-induced increase in NQO1 expression in BEAS-2B cells, supporting NRF2 dependence for that measured response.

Cannabidiol plus moringin, each at 5 micromolar, produced larger changes in inflammatory, oxidative and apoptosis markers in LPS-stimulated murine macrophages than either constituent alone at that concentration.

A TRPV1 antagonist impaired cannabidiol efficacy in the macrophage assay but did not alter moringin activity; CB1 and CB2 antagonists affected neither route.

In ten healthy adults, a single 4 g dose of Moringa leaf powder increased insulin AUC and the insulin-to-glucose AUC ratio by 74% compared with the no-Moringa baseline.

The same escalating-dose study found no difference in six-hour plasma glucose exposure after 0, 1, 2 or 4 g Moringa leaf powder.

In a 12-week double-blind trial in adults with prediabetes, 2.4 g/day Moringa dry leaf powder produced favorable fasting-glucose and HbA1c change scores relative to placebo.

The same 12-week trial found no between-group differences in gut microbiota composition, hepatic or renal function markers, or the measured appetite-controlling hormones.

An ancillary analysis of the same 12-week prediabetes trial found no between-group differences in inflammatory markers, serum lipids, plasma antioxidant capacity or blood pressure.

In a 40-person, 14-day randomized study of 20, 40 or 60 g/day Moringa leaves, adjusted end-of-intervention glucose, blood-pressure and lipid outcomes did not differ significantly among groups and changes were not dose-dependent.

In eleven evaluable adults with HIV, 1.85 g/day Moringa leaf powder for 14 days did not significantly alter steady-state nevirapine AUC, Cmax or 12-hour concentration.

In twenty healthy volunteers, concurrent Moringa leaf powder lowered amodiaquine Cmax, while seven-day pretreatment increased desethylamodiaquine Cmax and AUC; desethylamodiaquine AUC rose 40.4% with concurrent dosing and 188% after pretreatment.

Moringa methanolic and aqueous leaf extracts inhibited CYP3A4-mediated testosterone 6-beta-hydroxylation in mixed-sex human liver microsomes, with reported IC50 values of 0.5 and 2.5 mg/mL.

Several isolated Moringa leaf metabolites inhibited CYP3A4 at 41.5-100 micromolar but showed no remarkable CYP2D6 inhibition in the same in-vitro panel.

Adding 5% peanut oil to Moringa leaves during simulated digestion increased beta-carotene and lutein micellarization, particularly beta-carotene, before uptake by Caco-2 cells.

In fifteen well-nourished young children, intrinsically labeled beta-carotene from pureed Moringa leaves had 28% relative bioefficacy and an estimated vitamin A equivalence of 3.3:1 by weight.

In a six-week pilot feeding study, Moringa-fortified complementary foods produced only marginal, nonsignificant blood-retinol increases, and all infants remained vitamin A deficient.

In a three-month cluster-randomized pilot, 20 g/day maternal Moringa leaf powder did not change human-milk vitamin A concentration or maternal and infant serum vitamin A status, although milk alpha-carotene rose modestly.

Aqueous Moringa leaf extract inhibited alpha-amylase and reduced sucrose digestion across six tested gastrointestinal segments in rat and in-vitro experiments.

The same aqueous leaf extract retarded intestinal glucose absorption in rat perfusion experiments and bound glucose in a fiber assay.

In the type-2-diabetic rat experiment, Moringa extract did not significantly change pancreatic insulin concentration despite its effects on carbohydrate digestion and absorption.

Oral hydroethanolic Moringa leaf extract caused biochemical and histological liver and kidney injury in female ICR mice after a single 2000 mg/kg dose and during 28-day dosing up to 1000 mg/kg/day.

Availability and dependencies

The sources

Recorded disagreements

Open questions in this collection